41038-63-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(3-Bromopropyl)pyridine Hydrobromide is used as a synthetic intermediate for the preparation of thiophene and pyrrole derivatives. These derivatives are known for their ability to act as platelet aggregation inhibitors, which are crucial in the development of medications targeting conditions such as thrombosis and other blood clot-related disorders. 3-(3-Bromopropyl)pyridine Hydrobromide's reactivity and structural features make it a valuable component in the synthesis of these therapeutic agents, contributing to their effectiveness in treating the aforementioned medical conditions.

Upstream product

• 2859-67-8 3-(3-pyridyl)propan-1-ol 
• 108-99-6 3-Methylpyridine 

Downstream Products

• 106134-30-9 N-[3-(pyridin-3-yl)-propyl]-2,6-dimethylaniline 
• 134164-11-7 methyl 8-(p-chlorophenylsulfonamido)-4-[3-(pyridin-3-yl)propyl]-octanoate 
• 134235-78-2 CGS 22652 
• 1026685-95-9 8-(4-Azido-benzenesulfonylamino)-4-(3-pyridin-3-yl-propyl)-octanoic acid methyl ester 
• 1026605-63-9 8-(4-Methanesulfonyl-benzenesulfonylamino)-4-(3-pyridin-3-yl-propyl)-octanoic acid methyl ester 
• 1027416-24-5 6-(4-Methanesulfonyl-benzenesulfonylamino)-2-(3-pyridin-3-yl-propyl)-hexanoic acid ethyl ester 
• 1026168-68-2 6-(4-Azido-benzenesulfonylamino)-2-(3-pyridin-3-yl-propyl)-hexanoic acid ethyl ester 
• 1026953-61-6 4-(3-Pyridin-3-yl-propyl)-8-(4-trifluoromethyl-benzenesulfonylamino)-octanoic acid methyl ester 
• 1025802-93-0 2-(3-Pyridin-3-yl-propyl)-6-(4-trifluoromethyl-benzenesulfonylamino)-hexanoic acid ethyl ester 
• 1027235-53-5 4-Azido-N-(5-formyl-8-pyridin-3-yl-octyl)-benzenesulfonamide 
• 144409-93-8 methyl 8-<<(4-chlorophenyl)sulfonyl>amino>-4-<3-(3-pyridinyl)propyl>oct-2-enoate 
• 1026735-52-3 N-(5-Formyl-8-pyridin-3-yl-octyl)-4-methanesulfonyl-benzenesulfonamide 

Relevant academic research and scientific papers

(N-phthalimidoalkyl) piperidines useful as treatments for psychosis

There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.

CERTAIN (ARYLSULFONAMIDO- AND IMIDAZOLYL-)-SUBSTITUTED CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND USE FOR SUPPRESSING THROMBOXANE ACTIVITY

The present invention is concerned with compounds of formula I STR1 wherein A, B, M, R, Ar and Het are as defined in the specification, pharmaceutically acceptable ester and amide derivatives thereof; N-oxides thereof, tetrazole derivatives thereof, and s

(Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity

Disclosed are the compounds of formula STR1 wherein A represents lower alkylene; B represents oxygen, sulfur, lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl-, sulfonyl- or thio)-lower alkylene, lower al

On the mechanism of epoxidation of alkenes with hypochlorite, catalysed by manganese(III) tetraarylporphyrins

A detailed mechanistic study of the epoxidation of alkenes by the cytochrome-P-450 model sodium hypochlorite/manganese(III) tetraarylporphyrin is presented.From the zero-order rate dependence on alkene concentration and low-temperature-trapping experiment